Global Bone Marrow Biopsy Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Bone Marrow Biopsy Market Size

• The global bone marrow biopsy market size was valued at USD 1.40 billion in 2025 and is expected to reach USD 2.28 billion by 2033, at a CAGR of 6.30% during the forecast period
• The market growth is largely fueled by the increasing prevalence of hematological disorders such as leukemia, lymphoma, and anemia, along with rising demand for accurate diagnostic procedures, leading to increased adoption of bone marrow biopsy procedures in hospitals and diagnostic centers
• Furthermore, growing advancements in minimally invasive biopsy techniques, improved diagnostic accuracy, and rising awareness regarding early disease detection are establishing bone marrow biopsy as a critical component of hematology diagnostics. These converging factors are accelerating the uptake of Bone Marrow Biopsy solutions, thereby significantly boosting the industry's growth

Bone Marrow Biopsy Market Analysis

• Bone marrow biopsy procedures, used for the diagnosis and monitoring of hematological disorders such as leukemia, lymphoma, and anemia, are increasingly vital components of modern diagnostic healthcare systems due to their accuracy in detecting bone marrow abnormalities and guiding treatment decisions
• The escalating demand for bone marrow biopsy solutions is primarily fueled by the rising prevalence of blood-related disorders, increasing cancer incidence, growing need for early and precise diagnosis, and advancements in biopsy techniques and diagnostic technologies
• North America dominated the bone marrow biopsy market with the largest revenue share of 37.8% in 2025, driven by advanced healthcare infrastructure, high diagnostic rates, strong presence of key medical device companies, and widespread adoption of minimally invasive biopsy procedures in the U.S.
• Asia-Pacific is expected to be the fastest growing region in the bone marrow biopsy market during the forecast period due to increasing cancer burden, improving healthcare infrastructure, rising awareness about early diagnosis, and expanding access to advanced diagnostic procedures
• The posterior iliac crest segment dominated the largest market revenue share of around 49.2% in 2025, driven by its safety and high diagnostic success rate
• The adult segment dominated the largest market revenue share of around 52.8% in 2025, driven by the high prevalence of hematological disorders such as leukemia, lymphoma, and anemia among the adult population

Report Scope and Bone Marrow Biopsy Market Segmentation

Bone Marrow Biopsy Market Trends

“Advancements in Minimally Invasive and Image-Guided Biopsy Techniques”

• A significant and accelerating trend in the global Bone Marrow Biopsy market is the increasing adoption of minimally invasive and image-guided biopsy techniques, which enhance diagnostic accuracy while improving patient comfort and procedural efficiency
• For instance, the use of imaging modalities such as CT-guided or ultrasound-assisted bone marrow biopsy procedures is enabling clinicians to obtain more precise samples, particularly in complex or difficult anatomical cases
• Technological advancements in biopsy needles and aspiration devices are also contributing to reduced procedural pain and improved sample quality
• Growing emphasis on early and accurate diagnosis of hematological disorders, including leukemia, lymphoma, and anemia, is further supporting the adoption of advanced biopsy techniques
• In addition, integration of biopsy procedures with molecular diagnostics and pathology workflows is improving disease detection and treatment planning
• This trend toward more precise, efficient, and patient-friendly diagnostic procedures is significantly enhancing clinical outcomes and driving market growth

Bone Marrow Biopsy Market Dynamics

Driver

“Rising Prevalence of Hematological Disorders and Cancer Diagnosis”

• The increasing prevalence of hematological disorders and blood-related cancers is a major driver of the Bone Marrow Biopsy market, as these procedures are essential for accurate diagnosis and disease monitoring
• For instance, the growing incidence of leukemia and lymphoma globally is leading to a higher number of bone marrow biopsy procedures for definitive diagnosis and staging of these conditions
• In addition, rising awareness about early cancer detection and improved access to diagnostic healthcare services are contributing to increased procedure volumes
• The expanding use of bone marrow biopsy in monitoring treatment response and disease progression is further driving demand
• Growth in healthcare infrastructure and availability of specialized diagnostic centers are also supporting market expansion

Restraint/Challenge

“Procedure-Related Discomfort and Requirement for Skilled Professionals”

• The invasive nature of bone marrow biopsy procedures, which can cause pain, discomfort, and anxiety among patients, remains a key challenge for market growth
• For instance, patients undergoing bone marrow biopsy often experience procedural pain and post-procedure soreness, which may discourage individuals from opting for early diagnostic testing
• In addition, the requirement for highly skilled healthcare professionals to perform the procedure accurately can limit accessibility, especially in low-resource settings
• Risk of complications such as bleeding or infection, although minimal, can also impact patient acceptance
• Limited awareness and delayed diagnosis in certain regions further hinder timely adoption of biopsy procedures
• Addressing these challenges through improved pain management techniques, training of healthcare professionals, and increased awareness will be critical for sustained market growth

Bone Marrow Biopsy Market Scope

The market is segmented on the basis of product type, procedure type, biopsy type, site, technique, age, application, and end user.

• By Product Type

On the basis of product type, the Bone Marrow Biopsy market is segmented into needles, instruments, biopsy gun, procedure trays, and others. The needles segment dominated the largest market revenue share of around 38.6% in 2025, driven by its critical role in both aspiration and core biopsy procedures. Increasing prevalence of hematological disorders is supporting demand. Growing adoption of minimally invasive diagnostic tools is boosting usage. Rising awareness of early disease detection is increasing biopsy procedures. Expanding hospital infrastructure is improving access. Increasing use of disposable needles is enhancing safety and reducing infections. Growing demand for accurate sample collection is supporting adoption. Technological advancements in needle design are improving efficiency. Rising diagnostic procedures in oncology are strengthening demand. Increasing physician preference for reliable tools is boosting usage. Expanding diagnostic centers are supporting accessibility. Rising patient inflow is further strengthening segment growth.

The biopsy gun segment is expected to witness the fastest CAGR of around 8.5% from 2026 to 2033, driven by increasing demand for automated and efficient biopsy procedures. Biopsy guns improve precision and reduce procedure time. Growing preference for minimally invasive diagnostics is supporting adoption. Increasing use in oncology diagnostics is boosting demand. Expanding healthcare facilities are integrating advanced devices. Rising awareness of accurate diagnosis is supporting growth. Technological advancements are improving performance. Increasing adoption in ambulatory settings is driving demand. Growing physician preference for ease of use is boosting adoption. Rising need for consistent sampling is supporting growth. Expanding use in advanced clinical settings is strengthening demand. Increasing patient comfort is further boosting adoption.

• By Procedure Type

On the basis of procedure type, the Bone Marrow Biopsy market is segmented into hip biopsy, breastbone (sternum) biopsy, percutaneous trephine biopsy, tibia (shin) biopsy, and others. The hip biopsy segment dominated the largest market revenue share of around 42.1% in 2025, driven by its high success rate and widespread clinical preference. The posterior iliac crest provides reliable and sufficient marrow samples. Increasing prevalence of blood disorders is boosting demand. Growing physician preference for this site is supporting adoption. Expanding hospital procedures are increasing usage. Rising awareness of accurate diagnosis is strengthening demand. Increasing use in leukemia and lymphoma detection is boosting growth. Technological advancements are improving procedural outcomes. Growing patient safety awareness is supporting preference. Expanding healthcare infrastructure is improving access. Increasing diagnostic accuracy needs are strengthening demand.

The percutaneous trephine biopsy segment is expected to witness the fastest CAGR of around 8.2% from 2026 to 2033, driven by its ability to provide high-quality core tissue samples. Increasing demand for detailed histopathological analysis is supporting growth. Growing use in advanced diagnostic procedures is boosting adoption. Rising awareness of minimally invasive techniques is strengthening demand. Expanding oncology research is increasing usage. Technological advancements are improving procedure efficiency. Increasing preference for accurate tissue architecture analysis is supporting adoption. Growing clinical expertise is enhancing outcomes. Rising demand for precise diagnostics is boosting growth. Expanding use in specialized centers is supporting adoption. Increasing patient preference for effective diagnosis is strengthening demand.

• By Biopsy Type

On the basis of biopsy type, the Bone Marrow Biopsy market is segmented into core needle biopsy, vacuum-assisted biopsy (VAB), and fine needle aspiration biopsy. The core needle biopsy segment held the largest market revenue share of around 47.3% in 2025, driven by its ability to provide detailed tissue samples for accurate diagnosis. Increasing prevalence of cancer is supporting demand. Growing need for histopathological examination is boosting adoption. Expanding use in hospitals and diagnostic centers is strengthening growth. Rising awareness of early cancer detection is supporting procedures. Technological advancements are improving biopsy accuracy. Increasing physician preference for reliable methods is boosting usage. Growing patient awareness is supporting diagnostic uptake. Expanding healthcare infrastructure is improving accessibility. Rising use in oncology is strengthening demand. Increasing need for precise diagnosis is boosting adoption.

The vacuum-assisted biopsy (VAB) segment is expected to witness the fastest CAGR of around 8.9% from 2026 to 2033, driven by its ability to obtain larger tissue samples with fewer insertions. Increasing demand for minimally invasive procedures is supporting growth. Growing focus on patient comfort is boosting adoption. Expanding use in advanced oncology diagnostics is increasing demand. Technological advancements are improving device efficiency. Rising awareness of accurate diagnosis is supporting growth. Increasing adoption in specialized centers is boosting usage. Growing demand for precision medicine is strengthening adoption. Rising healthcare investments are supporting expansion. Increasing use in complex cases is driving growth.

• By Site

On the basis of site, the Bone Marrow Biopsy market is segmented into posterior iliac crest, anterior iliac crest, calcaneus, distal tibia, proximal tibia, proximal humerus, and others. The posterior iliac crest segment dominated the largest market revenue share of around 49.2% in 2025, driven by its safety and high diagnostic success rate. It is the most preferred site for bone marrow biopsy procedures. Increasing physician familiarity is supporting demand. Growing patient safety awareness is boosting adoption. Expanding diagnostic procedures are strengthening usage. Rising prevalence of hematological disorders is increasing demand. Increasing hospital-based procedures are supporting growth. Technological advancements are improving accuracy. Growing awareness of early detection is boosting adoption. Expanding healthcare infrastructure is improving access. Increasing training of healthcare professionals is enhancing outcomes. Rising diagnostic demand is strengthening dominance.

The anterior iliac crest segment is expected to witness the fastest CAGR of around 7.8% from 2026 to 2033, driven by its use in patients where posterior access is limited. Increasing demand for alternative biopsy approaches is supporting growth. Growing awareness of flexible biopsy techniques is boosting adoption. Expanding clinical expertise is improving usage. Rising patient-specific treatment approaches are supporting demand. Increasing use in complex cases is driving growth. Growing adoption in specialized settings is strengthening demand. Rising advancements in biopsy techniques are improving outcomes. Increasing healthcare accessibility is supporting expansion. Growing patient comfort considerations are boosting adoption.

• By Technique

On the basis of technique, the Bone Marrow Biopsy market is segmented into flow cytometry, fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), karyotype test, and others. The flow cytometry segment held the largest market revenue share of around 36.7% in 2025, driven by its rapid and accurate cell analysis capabilities. Increasing use in leukemia and lymphoma diagnosis is supporting demand. Growing adoption in clinical laboratories is boosting growth. Expanding diagnostic capabilities are improving access. Rising awareness of advanced diagnostics is strengthening usage. Increasing use in research applications is supporting demand. Technological advancements are enhancing efficiency. Growing need for precise cell characterization is boosting adoption. Expanding healthcare infrastructure is improving availability. Rising patient volume is strengthening demand. Increasing preference for rapid diagnostics is supporting growth.

The PCR segment is expected to witness the fastest CAGR of around 9.3% from 2026 to 2033, driven by its high sensitivity in detecting genetic mutations. Increasing adoption in molecular diagnostics is boosting growth. Rising demand for personalized medicine is supporting usage. Expanding research in genetic disorders is strengthening adoption. Growing awareness of precision diagnostics is supporting demand. Technological advancements are improving accessibility. Increasing use in oncology is boosting growth. Rising healthcare investment is supporting expansion. Growing demand for early detection is strengthening adoption. Increasing use in advanced diagnostics is supporting growth.

• By Age

On the basis of age, the Bone Marrow Biopsy market is segmented into geriatric, adult, and pediatric. The adult segment dominated the largest market revenue share of around 52.8% in 2025, driven by the high prevalence of hematological disorders such as leukemia, lymphoma, and anemia among the adult population. Increasing awareness regarding early diagnosis and rising routine health check-ups are supporting demand. Adults are more likely to undergo diagnostic procedures due to better healthcare access and insurance coverage. The growing burden of chronic diseases and cancer incidence is further fueling biopsy procedures. Availability of advanced diagnostic facilities in hospitals is enhancing adoption. Rising physician recommendations for early detection also contribute to dominance. Technological advancements in minimally invasive biopsy techniques are improving patient compliance. Increasing healthcare expenditure among the working population supports growth. Additionally, lifestyle-related disorders are increasing diagnostic needs. Strong presence of diagnostic centers further strengthens this segment.

The geriatric segment is expected to witness the fastest CAGR of around 8.7% from 2026 to 2033, driven by the rapidly aging global population and higher susceptibility to bone marrow-related disorders. Elderly individuals have a higher risk of cancers such as multiple myeloma and leukemia, boosting demand for biopsy procedures. Increasing life expectancy and improved healthcare access are contributing to growth. Government initiatives for elderly healthcare support are further accelerating adoption. Rising demand for personalized and precise diagnostics in geriatric care is also a key factor. Improved reimbursement policies in developed regions are enhancing procedure uptake. Advancements in less invasive biopsy techniques are making procedures safer for older patients. Growing focus on early disease detection in aging populations is boosting demand. Expansion of geriatric care facilities and specialty clinics is also contributing. Increasing clinical research in age-related disorders further supports segment growth.

• By Application

On the basis of application, the Bone Marrow Biopsy market is segmented into lymphoma disease, leukemia, polycythemia vera, multiple myeloma, thrombocythemia, myelofibrosis, aplastic anemia, and others. The leukemia segment dominated the largest market revenue share of around 40.4% in 2025, driven by high global prevalence and diagnostic demand. Increasing awareness of blood cancers is supporting growth. Rising diagnostic procedures are boosting adoption. Expanding healthcare access is improving early detection. Growing use in treatment monitoring is supporting demand. Increasing research in oncology is strengthening growth. Rising patient awareness is boosting screening rates. Expanding hospital infrastructure is improving access. Increasing use of advanced diagnostics is supporting growth. Growing focus on early diagnosis is strengthening demand. Increasing healthcare spending is boosting adoption.

The multiple myeloma segment is expected to witness the fastest CAGR of around 8.6% from 2026 to 2033, driven by increasing incidence among aging populations. Growing awareness of rare cancers is supporting diagnosis. Expanding use of advanced biopsy techniques is boosting growth. Rising healthcare expenditure is supporting treatment access. Increasing research is improving diagnosis rates. Growing demand for early detection is strengthening adoption. Expanding oncology centers is supporting growth. Rising physician awareness is boosting diagnosis. Increasing use of targeted therapies is supporting demand. Growing patient awareness is strengthening adoption.

• By End User

On the basis of end user, the Bone Marrow Biopsy market is segmented into hospitals, diagnostic centers, ambulatory surgical centers, academic and research organizations, and others. The hospitals segment dominated the largest market revenue share of around 52.3% in 2025, driven by availability of advanced diagnostic and treatment infrastructure. Increasing patient inflow is supporting demand. Expanding healthcare investment is improving facilities. Growing awareness of early diagnosis is boosting hospital visits. Rising use of biopsy in oncology is supporting growth. Increasing insurance coverage is improving access. Expanding laboratory integration is enhancing diagnosis. Rising referrals are strengthening demand. Growing adoption of advanced technologies is supporting growth. Increasing availability of skilled professionals is boosting outcomes.

The diagnostic centers segment is expected to witness the fastest CAGR of around 8.8% from 2026 to 2033, driven by increasing preference for specialized diagnostic services. Expanding standalone labs are supporting growth. Rising demand for quick and accurate results is boosting adoption. Increasing healthcare accessibility is supporting expansion. Growing awareness of early diagnosis is strengthening demand. Expanding urban healthcare infrastructure is improving access. Rising technological advancements are supporting efficiency. Increasing patient preference for outpatient diagnostics is boosting growth. Growing affordability is supporting adoption.

Bone Marrow Biopsy Market Regional Analysis

• North America dominated the bone marrow biopsy market with the largest revenue share of 37.8% in 2025, driven by advanced healthcare infrastructure, high diagnostic rates, strong presence of key medical device companies, and widespread adoption of minimally invasive biopsy procedures in the U.S.
• Patients in the region benefit from early disease detection programs, strong access to specialized hematology and oncology services, and high utilization of advanced diagnostic technologies for accurate disease evaluation
• This widespread adoption is further supported by high healthcare expenditure, well-established hospital networks, and availability of skilled healthcare professionals, establishing North America as a leading region in diagnostic procedure adoption

U.S. Bone Marrow Biopsy Market Insight

The U.S. bone marrow biopsy market captured the largest revenue share within North America in 2025, driven by a high prevalence of hematological disorders and strong access to advanced diagnostic healthcare services. Increasing focus on early cancer detection and disease monitoring is leading to higher demand for bone marrow biopsy procedures. The presence of leading healthcare institutions, advanced laboratory infrastructure, and skilled professionals is further supporting market growth. In addition, continuous technological advancements in minimally invasive biopsy techniques are improving diagnostic accuracy and patient outcomes.

Europe Bone Marrow Biopsy Market Insight

The Europe bone marrow biopsy market is projected to expand at a substantial CAGR throughout the forecast period, driven by increasing incidence of blood-related disorders and strong public healthcare systems. Rising awareness regarding early diagnosis of conditions such as leukemia and lymphoma is supporting higher adoption of biopsy procedures. In addition, well-established diagnostic infrastructure and growing investments in healthcare are contributing to market growth. The region is also witnessing increased use of advanced imaging-guided biopsy techniques.

U.K. Bone Marrow Biopsy Market Insight

The U.K. bone marrow biopsy market is anticipated to grow at a noteworthy CAGR during the forecast period, supported by rising cancer incidence and increasing demand for accurate diagnostic procedures. Patients are increasingly opting for early diagnostic testing due to improved awareness and access to healthcare services. The presence of a strong public healthcare system and availability of specialized diagnostic centers is enhancing procedure accessibility. In addition, advancements in pathology and laboratory services are supporting market expansion.

Germany Bone Marrow Biopsy Market Insight

The Germany bone marrow biopsy market is expected to expand at a considerable CAGR during the forecast period, driven by advanced healthcare infrastructure and strong emphasis on diagnostic accuracy. Increasing prevalence of hematological conditions and rising awareness about early disease detection are contributing to market growth. Germany’s focus on technological innovation and precision diagnostics is further improving biopsy procedures. In addition, availability of skilled healthcare professionals and modern clinical facilities is strengthening market development.

Asia Pacific Bone Marrow Biopsy Market Insight

Asia-Pacific bone marrow biopsy market is expected to be the fastest growing region in the Bone Marrow Biopsy market during the forecast period due to increasing cancer burden, improving healthcare infrastructure, rising awareness about early diagnosis, and expanding access to advanced diagnostic procedures. Rapid urbanization, growing patient population, and increasing prevalence of hematological disorders in countries such as China, India, and Japan are further driving demand for diagnostic procedures. Government initiatives to strengthen healthcare systems and expand access to cancer diagnostics are also supporting strong market growth across the region

Japan Bone Marrow Biopsy Market Insight

The Japan bone marrow biopsy market is gaining steady momentum due to the country’s advanced healthcare system and rising focus on early disease detection. Increasing incidence of blood disorders and cancer is driving demand for accurate diagnostic procedures. The country’s strong adoption of advanced medical technologies and well-developed hospital infrastructure is supporting market growth. In addition, access to skilled specialists is improving patient outcomes.

China Bone Marrow Biopsy Market Insight

The China bone marrow biopsy market accounted for the largest market revenue share in Asia-Pacific in 2025, supported by a large patient population and rising prevalence of cancer and blood-related disorders. Increasing awareness about early diagnosis and improving access to healthcare services are driving demand for biopsy procedures. In addition, rapid healthcare infrastructure development, growing investments in diagnostic technologies, and expanding hospital networks are further strengthening market growth.

Bone Marrow Biopsy Market Share

The Bone Marrow Biopsy industry is primarily led by well-established companies, including:

• Becton, Dickinson and Company (U.S.)
• Cardinal Health, Inc. (U.S.)
• Cook Medical (U.S.)
• Argon Medical Devices, Inc. (U.S.)
• Merit Medical Systems, Inc. (U.S.)
• Medtronic plc (Ireland)
• Boston Scientific Corporation (U.S.)
• Olympus Corporation (Japan)
• Hologic, Inc. (U.S.)
• Teleflex Incorporated (U.S.)
• GE HealthCare Technologies Inc. (U.S.)
• Siemens Healthineers AG (Germany)
• FUJIFILM Holdings Corporation (Japan)
• Devicor Medical Products, Inc. (U.S.)
• Stryker Corporation (U.S.)
• Smith & Nephew plc (U.K.)
• CONMED Corporation (U.S.)
• INRAD, Inc. (U.S.)
• AngioDynamics, Inc. (U.S.)
• Tsunami Medical S.r.l. (Italy

Latest Developments in Global Bone Marrow Biopsy Market

• In June 2021, the U.S. FDA announced a Class II recall of Jamshidi Bone Marrow Biopsy/Aspiration Needles due to packaging seal issues that could compromise sterility. This development highlighted quality and safety concerns in biopsy device manufacturing and reinforced regulatory scrutiny in the market
• In April 2023, researchers from Gujarat Cancer Research Institute (GCRI) and IITRAM developed and patented a novel bone marrow biopsy device designed to improve accuracy and reduce complications during tissue extraction. The device incorporates depth sensing and pressure control mechanisms to minimize risks such as bone damage and over-penetration
• In October 2023, Praxis Medical received U.S. FDA 510(k) clearance for its EndoCore EBUS-TBNA biopsy device, a motorized fine-needle system designed to enhance tissue sampling efficiency during biopsy procedures. This reflects ongoing innovation in biopsy technologies that can influence bone marrow biopsy techniques as well
• In January 2025, Zhejiang Curaway Medical Technology Co., Ltd. received U.S. FDA 510(k) clearance for a Bone Marrow Biopsy Needle, confirming its substantial equivalence to existing devices and enabling commercialization in the U.S. market. This approval supports expansion of advanced biopsy instruments globally
• In March 2026, the U.S. FDA reported supply chain challenges affecting biopsy needles, including shortages and recalls impacting manufacturers such as Hologic, highlighting ongoing supply and manufacturing pressures in the biopsy devices segment. These disruptions can indirectly impact availability of bone marrow biopsy tools

SKU-53897